Immuno-Cluster
Autologous immuno-hybridoma have been applied to treat prostate cancer resistant castration revealing that this approach is a safe, non-toxic significant immunity response to significantly prolong the time to secondary therapy. The aim of the project is to create a Cross-border Immuno-Cluster through a clinical experimentation for the treatment of the triple negative breast carcinoma, an aggressive cancer not yet treatable, by an autologous vaccine of cellular immunohybridoma, whose production will be made scalable to meet product needs. The project will be an excellence to put together cutting-edge hospitals, pharmaceutical and biotechnology companies, universities and research centers, which are all relevant European and global players. Activities of partners will be synchronized, bringing them together in an innovative approach with a strong impact in immunotherapy breast cancer clinic. Project partners will achieve two parallel objectives: a) introduce a safe and effective approach to treat triple negative breast cancer (clinical protocol) still missing today, and b) develop a set of common goods (qualified personnel, infrastructure, know-how) on which hospitals, universities, SMEs, start-ups and investors will be able to build their own offers.